Pascalis Vergidis MD, MS
@pascalisID
Followers
2K
Following
3K
Media
96
Statuses
536
Associate Professor @MayoClinicINFD | Microbiology Course Director @MayoClinicSOM | Governance @ABIMCert | Member-At-Large @MSG_ERC | Editor @JournalSpectrum
Mayo Clinic Rochester, MN
Joined April 2019
Looking forward to our journal club @MayoClinicINFD . Adjunctive corticosteroids in hypoxemic patients with non-HIV Pneumocystis pneumonia. No difference in 28-day mortality. However, need for mechanical ventilation was lower in the steroid group. https://t.co/4xe6tWhoMx
0
3
6
As a member of the Infectious Disease Approval Committee @ABIMcert, I would like to congratulate those who recently passed their Boards. You are all committed to delivering exceptional patient care and upholding the highest standards in Medicine.
0
0
8
Dr @jamchugh presenting his work on cytokine release syndrome and related infections in patients with CAR T cell treatment. Excellent work! Congrats to the entire team! @pascalisID
0
2
20
Please join us this Monday 8-9 am at IDWeek. Difficult-to-treat mold infections. Dimitrios Farmakiotis discussing treatment of mucormycosis. I will be discussing treatment of aspergillosis.
1
1
39
Programs today are mainly judged based on work hour compliance and satisfaction surveys but have no accountability for their trainees’ initial placement and early career path. The latter is a metric of utmost importance; the relationship should not end at the graduation dinner.
7
9
105
Clinical and microbiologic features of Achromobacter species: a 10-year, multicenter experience @ASMicrobiology
https://t.co/kayxd6v4aV
journals.asm.org
Achromobacter is a rare but important genus of bacteria that tends to cause infection in those with cystic fibrosis, recurrent healthcare exposures, and/or an immunocompromising condition. There is...
0
6
13
This graph shows a U.S. public health triumph: near-elimination of pediatric hepatitis B through universal birth vaccination. After 30 years of extraordinary progress, ACIP tomorrow considers dismantling it. Medical justification: none. Consequences: catastrophic.
81
457
1K
Thursday AM conference at @MayoClinicINFD where our excellent senior fellows @MKerkelis and @jamchugh present 6 rapid review cases. At our fellowship, Thursday AM conference presents one of the many opportunities for fellows/residents to teach the division. 📖 👓
1
2
20
I learned a lot by attending the lecture of Dallas Smith @CDCgov on chromoblastomycosis and eumycetoma. ASM Microbe 2025
1
1
11
【Blastemia portrays a poor prognosis in acute leukemia patients with invasive pulmonary aspergillosis】 Excited to share our recent article on the “B-index” in invasive pulmonary aspergillosis! @MDAndersonNews In addition to the D-index, blastemia is an important prognostic
1
9
20
🔥🗞️Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Groundbreaking work on a very promising new antifungal. Free access here: https://t.co/rh58X00hvP
0
20
31
Join us for a panel discussion on “Leveraging Partnerships to Fight Fungal Diseases” @ASMicrobiology Dallas Smith @CDCgov Sean Zhang, Fungal Diagnostics Laboratory Consortium Rob Purdie, MYCology Advocacy, Research & Education Zachary Rubin @lapublichealth Me @MSG_ERC
0
4
9
Join us for a panel discussion on “Leveraging Partnerships to Fight Fungal Diseases” @ASMicrobiology Dallas Smith @CDCgov Sean Zhang, Fungal Diagnostics Laboratory Consortium Rob Purdie, MYCology Advocacy, Research & Education Zachary Rubin @lapublichealth Me @MSG_ERC
0
4
9
Visited the historic city of Philadelphia to attend the American Board of Internal Medicine (ABIM) New Governance Orientation. Looking forward to serving on the Infectious Disease Approval Committee. Of the profession, for the public @ABIMcert
0
1
17
Visited the historic city of Philadelphia to attend the American Board of Internal Medicine (ABIM) New Governance Orientation. Looking forward to serving on the Infectious Disease Approval Committee. Of the profession, for the public @ABIMcert
0
1
17
Synthesis of the available literature on the use of CMV-specific T-cell therapy in adult and pediatric HSCT and SOT recipients. Several patients on concurrent antivirals, which confounded the effectiveness of VSTs @CIDJournal @TransplantIDNet
https://t.co/dF0DxsEvOv
academic.oup.com
Cytomegalovirus-specific T cells have been used in studies of primarily adult hematopoietic stem cell transplant recipients. Heterogenous trial design and
0
5
9
Dr. Jeniel Nett discussing biofilm at the 2025 Scientific Meeting on Candida auris @MSG_ERC Successful meeting held in Miami.
0
0
6
High Kaposi sarcoma-associated herpesvirus seroprevalence in donors and recipients with HIV, particularly among MSM. Reassuringly, disease was rare @CIDJournal @TransplantIDNet
https://t.co/Z5QXjDXw4o
academic.oup.com
The prevalence of Kaposi sarcoma–associated herpesvirus (KSHV) was high among kidney donor and transplant recipients with HIV. Posttransplant KSHV-associat
0
3
13
In a phase 3 clinical trial, pemivibart provided prophylactic efficacy against COVID-19 in immunocompromised patients and individuals at risk for exposure. Four of 623 participants experienced anaphylactic reactions @CIDJournal @TransplantIDNet
https://t.co/clv9ZdOczN
academic.oup.com
Preexposure prophylactic administration of 2 doses of pemivibart approximately 90 days apart was generally well tolerated by most participants and provided
0
0
9